SEC Form 4 · accession 0000899243-16-011568
Aldeyra Therapeutics, Inc. · ALDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David J Clark
Officer — Chief Medical Officer
Period of report
Jan 11, 2016
Accepted (ET)
Jan 12, 2016 · 5:45 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001341235
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $6.76 | Jan 11, 2016 | A | 100,000 | A | — | Jan 11, 2026 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F125% of the shares shall vest after 12 months of continuous service with the Issuer, the balance will vest in equal monthly installments over the next 36 months of continuous service with the Issuer.